[{"id":"598dad60-4db5-446b-b113-901a396731ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05776407","created_at":"2023-03-20T19:02:54.113Z","updated_at":"2024-07-02T16:35:52.987Z","phase":"Phase 1/2","brief_title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","source_id_and_acronym":"NCT05776407","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • fludarabine IV • ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-03-20"},{"id":"bbe59d28-d934-4e00-a784-01daf74e8e90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05576181","created_at":"2022-10-12T13:56:47.128Z","updated_at":"2024-07-02T16:36:02.594Z","phase":"Phase 1","brief_title":"Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05576181","lead_sponsor":"Fundamenta Therapeutics, Ltd.","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/15/2022","start_date":" 10/15/2022","primary_txt":" Primary completion: 01/22/2025","primary_completion_date":" 01/22/2025","study_txt":" Completion: 07/22/2025","study_completion_date":" 07/22/2025","last_update_posted":"2022-10-12"},{"id":"32c24bdb-718c-4a35-a172-afb3477afdce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05535673","created_at":"2022-09-10T11:56:30.321Z","updated_at":"2024-07-02T16:36:04.124Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","source_id_and_acronym":"NCT05535673","lead_sponsor":"Zhengzhou University","biomarkers":" BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-09-12"}]